Oncology MRI

Latest News


CME Content


MRI Findings Show Vorasidenib More Than Doubles Progression-Free Survival in Patients with Grade 2 IDH Gliomas

For patients with residual or recurrent grade 2 isocitrate dehydrogenase (IDH)-mutant gliomas, magnetic resonance imaging (MRI) revealed that daily dosing of vorasidenib, an inhibitor of mutant IDH1 and IDH2 enzymes, led to a median progression-free survival of 27.7 months in comparison to 11.1 months in a placebo group, according to new research presented at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago.

New ACR Guidelines Emphasize Earlier Breast Cancer Screening for High-Risk Women

While calling for a universal breast cancer risk assessment by the age of 25, the American College of Radiology (ACR) emphasized that ascertaining screening needs prior to the age of 40 is particularly important in high-risk populations such as Black women, who are 42 percent more likely to die from breast cancer in comparison to non-Hispanic White women.